Abstract
Topical steroids are frequently used in itchy diseases. They are very effective in inflammatory dermatoses but there is no indication in other conditions because there is no known specific effect on itch. On the contrary, the topical calcineurin tacrolimus and pimecrolimus, that are indicated in atopic dermatitis, have specific effects on itch and could probably used in many other conditions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Van Laarhoven AI, van der Saman-Mauriks IM, Donders AR, Pronk MC, van de Kerkhof PC, Evers AW. Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions. J Invest Dermatol. 2015;135:1234–43.
Evers AW, Bartels DJ, van Laarhoven AI. Placebo and nocebo effects in itch and pain. Handb Exp Pharmacol. 2014;225:205–14.
Fujii Y, Sengoku T, Takakura S. Repeated topical application of glucocorticoids augments irritant chemical-triggered scratching in mice. Arch Dermatol Res. 2010;302:645–52.
Yamaura K, Doi R, Suwa E, Ueno K. Repeated application of glucocorticoids exacerbate pruritus via inhibition of prostaglandin D2 production of mast cells in a murine model of allergic contact dermatitis. J Toxicol Sci. 2012;37:1127–34.
Sher LG, Chang J, Patel IB, Balkrishnan R, Fleischer AB. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92:455–61.
Meurer M, Fölster-Horst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002;205:271–7.
Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539–46.
Stander S, Schürmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag. 2006;2:213–8.
Suys E. Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani. J Am Acad Dermatol. 2012;66:327–8.
Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol. 2001;44:995–8.
Cherill R, Tofte S, MacNaul R, et al. SDZ ASM 981 1% cream is effective in the treatment of chronic irritant hand dermatitis. J Eur Acad Dermatol Venereol. 2000;14 Suppl 1:128.
Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-versus-host disease: a case series of 18 patients. Arch Dematol. 2001;137:1202–6.
Böhm M, Friedling U, Luger TA, et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003;139:922–4.
Banky JP, Sheridan AT, Storer EL, et al. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol. 2004;140:794–6.
Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz S, et al. Succesful treatment of pruritus with topical tacrolimus in a patient with primary biliray cirrhosis. Br J Dermatol. 2005;152:808–9.
Kuypers DR, Claes K, Evenpoel P, et al. A prospective proof of concept study of the efficacy of tacrolimus ointmenton uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant. 2004;19:1895–901.
Duque MI, Yosipovitch G, Fleischer AB, et al. Lack of efficacy of tacrolimus ointment O.1% for treatment of hemodialysis-related pruritus: a randomizeddouble-blinded, vehicle-controlled study. J Am Acad Dermatol. 2005;52:519–21.
Rustin MHA. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol. 2007;157:861–73.
Calza AM, Lübbe J. Tacrolimus ointment-associated alcohol intolerance in infants receiving ethanol-conatining medication. Br J Dermatol. 2005;152:569.
Milingou M, Antille C, Sorg O, Saurat JH, Lübbe J. Alcohol intolerance and facial flushing in patients treated with topical tacrolimus. Arch Dermatol. 2004;140:1542–4.
Trevisani M, Smart D, Gunthorpe MJ, et al. Ethanol elicits and potentiates nociceptor response via the vanilloid-receptor 1. Nat Neurosci. 2002;5:546–51.
Stander S, Luger TA. Antipruritic effects of pimecrolimus and tacrolimus. Hautartzt. 2003;54:413–7.
Senba E, Katanosaka K, Yajima H, et al. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res. 2004;50:257–62.
Stander S, Stander H, Seelinger S, Luger TA, Steinhoff M. Topical tacrolimus and pimecrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol. 2007;156:1020–6.
Pereira U, Boulais N, Lebonvallet N, Pennec JP, Dorange G, Misery L. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol. 2010;163:70–7.
Xie ZQ, Yang GY, Jiang W, Xu ML. Antipruritic mechanisms of pimecrolimus cream for facial dermatitis in adult women patients. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009;31:27–30.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag London
About this chapter
Cite this chapter
Misery, L. (2016). Topical Steroids and Immunomodulators. In: Misery, L., Ständer, S. (eds) Pruritus. Springer, Cham. https://doi.org/10.1007/978-3-319-33142-3_46
Download citation
DOI: https://doi.org/10.1007/978-3-319-33142-3_46
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33140-9
Online ISBN: 978-3-319-33142-3
eBook Packages: MedicineMedicine (R0)